Clinical Experience with a Pasteurised Human Plasma Concentrate in Factor XIII Deficiency

Summary

A three-day-old infant presented with umbilical haemorrhage. Factor XIII deficiency was diagnosed. When one month old she commenced prophylactic injections of pasteurised factor XIII concentrate of human plasma origin. During two and a half years treatment there were no haemorrhagic episodes and factor XIII concentrate was well tolerated. Satisfactory post infusion factor XIII levels were achieved. Three transient elevations of aspartate transaminase occurred, the cause of which has not been established. There was no evidence of transmission of hepatitis or H.I.V. infection. A brother, born one year later, is also affected and commenced prophylactic therapy with the same factor XIII concentrate. Experience in these two infants suggests the product is efficacious.

Keywords

Factor XIII deficiency - Pasteurised concentrate

• References

• 1 Lorand L, Losowsky M, Miloszewski K. Human Factor XIII Fibrin Stabilizing Factor. In: Progress in Haemostasis and Thrombosis. Spaet TH. Ed. Vol.5 pp 245-290 Grune and Stratton; New York: 1980
• 2 Duckert F, Jung E, Shmerling DH. A hitherto undescribed congenital haemorrhagic diasthesis probably due to fibrin stabilizing factor deficiency. Thromb Diath Haemorrh 1960; 5: 179-186
• 3 Fear JD, Miloszewski KJ A, Losowsky MS. The half-life of Factor XIII in the management of inherited deficiency. Thromb Haemostas 1983; 49: 102-105
• 4 Losowsky MS, Miloszewski K. Management of patients with congenital deficiency of Fibrin Stabilizing Factor (factor XIII). In: Proceedings of the International Congress of Haematology. Seno,Takaku, Irino. Eds Excerpta Medica 1977. Kyoto; Japan: 1976
• 5 Winkelman L, Sims GE, Haddon ME, Evans DR, Smith JK. A Pasteurised Concentrate of Human Plasma Factor XIII for Therapeutic Use. Thromb Haemostas 1986; 55: 402-405
• 6 Curtis CG, Lorand L. Fibrin stabilizing factor (Factor XIII). Meth Enzy 1976; 45: 177-191
• 7 Duckert F, McDonagh J. Report of the sub-committee on Factor XIII (ISTS). Thromb Haemostas 1979; 41: 460-461
• 8 Austin DE G, Rhymes IL. Laboratory Manual of Blood Coagulation. p 63 Blackwell Scientific Publications; Oxford: 1975
• 9 Sheltawy MJ, Miloszewski K, Losowsky MS. Factors affecting Factor XIII assay by dansyl-cadaverine incorporation. Thromb Diathes Haemorrh 1972; 28: 483-488
• 10 Board PG, Coggan M, Hamer JW. An electrophoretic and quantitative analysis of coagulation Factor XIII in normal and deficient subjects. Brit J Haematol 1980; Vol.45 pp 633-640
• 11 Berliner SH, Lusky A, Zivelin A, Modan M, Seligsohn U. Hereditary Factor XIII Deficiency: Report of Four Families and Definition of the Carrier State. Brit J Haematol 1984; 56: 495-501
• 12 Kernoff PB A, Lee CA, Karayiannis P, Thomas HC. High risk of non-A, non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effect of prophylactic immune serum globulin. Brit J Haematol 1985; 60: 469-480
• 13 Colombo M, Mannucci PM, Carnelli V, Savidge GF, Gazengel C, Schimpf K. Transmission of non-A, non-B hepatitis by heat-treated Factor VIII concentrate. Lancet 1985; ii: 1-4
• 14 Tabor E. The three viruses of non-A, non-B hepatitis. Lancet 1985; i: 743-745